J. King

发表

Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis

J. Lechner-Scott, M. Slee, J. Correale, 2013, PloS one.

hypertension . without benign intracranial with the empty sella syndrome Intracranial pressure in patients

A. Kaye, B. Tress, J. King, 2003 .

Intracranial pressure in patients with the empty sella syndrome without benign intracranial hypertension.

A. Kaye, B. Tress, J. King, 1982, Journal of neurology, neurosurgery, and psychiatry.

The clinical profile of NMOSD in Australia and New Zealand

K. Dear, S. Broadley, J. Lechner-Scott, 2020, Journal of Neurology.

Cerebral venography and manometry in idiopathic intracranial hypertension

B. Tress, K. Thomson, J. King, 1995, Neurology.

Manometry combined with cervical puncture in idiopathic intracranial hypertension

B. Tress, K. Thomson, J. King, 2002, Neurology.

Transverse sinus septum: a new aetiology of idiopathic intracranial hypertension?

B. Tress, N. Eizenberg, R. Subramaniam, 2004, Australasian radiology.

Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation

S. Broadley, J. Lechner-Scott, M. Slee, 2020, Frontiers in Neurology.

Immunotherapy of Ocular Myasthenia Gravis Reduces Conversion to Generalized Myasthenia Gravis

J. King, E. Byrne, M. Paine, 2003, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

L. Kappos, C. Polman, H. Weiner, 2007, The Lancet Neurology.

Increased intracranial pressure following bilateral neck dissection and radiotherapy.

L. Kiers, J. King, 1991, The Australian and New Zealand journal of surgery.

Cerebral systemic lupus erythematosus.

M. F. Smith, J. King, A. M. Ward, 1988, Archives of disease in childhood.

Intracranial pressure following optic nerve decompression for benign intracranial hypertension. Case report.

A. Kaye, J. King, J. Galbraith, 1981, Journal of neurosurgery.

Recanalisation and outcome cerebral venous thrombosis

S. Davis, B. Tress, J. King, 1996, Journal of Clinical Neuroscience.

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

Ludwig Kappos, Jan Hillert, Gilles Edan, 2007, The Lancet Neurology.

Ischaemic optic neuropathy.

J. King, 1979, Clinical and experimental neurology.

Nitrous oxide myelopathy in an abuser of whipped cream bulbs

H. Butzkueven, J. King, 2000, Journal of Clinical Neuroscience.

Computed tomography of rhinocerebral mucormycosis

B. Tress, J. King, C. Kilpatrick, 2004, Neuroradiology.

Dentatorubral‐pallidoluysian atrophy in three generations, with clinical courses from nearly asymptomatic elderly to severe juvenile, in an Australian family of Macedonian descent

E. Storey, P. Mitchell, M. Fahey, 2005, American journal of medical genetics. Part A.

A new era in the treatment of multiple sclerosis

Jeannette Lechner-Scott, Helmut Butzkueven, John King, 2015, The Medical journal of Australia.

Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.

P. Sørensen, G. Giovannoni, B. Stubinski, 2007, Clinical therapeutics.

PRISMS-4: Long-term efficacy of interferon-&bgr;-1a in relapsing MS

Richard A. C. Hughes, H P Hartung, F Barkhof, 2001, Neurology.

Intracranial dural granulomas secondary to operative use of oxidised cellulose

J. King, C. Mclean, E. Popovic, 1996, Journal of Clinical Neuroscience.

Spinal leptomeningeal lymphoma presenting as pseudotumor syndrome.

Ruta Gupta, M. Buckland, J. King, 2013, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

Primary empty sella syndrome and benign intracranial hypertension.

B. Tress, J. King, S. Davis, 1978, Clinical and experimental neurology.

The correlation of clinical phenotype in Friedreich ataxia with the site of point mutations in the FRDA gene

R. Williamson, M. Delatycki, N. Nassif, 1998, Neurogenetics.

Treatment of caroticocavernous fistulae with detachable balloons introduced by percutaneous catheterization

B. Tress, K. Thomson, J. King, 1983, The Medical journal of Australia.

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 3 Treatment practicalities and recommendations

S. Broadley, J. Lechner-Scott, M. Slee, 2014, Journal of Clinical Neuroscience.

Fetal valproate syndrome and autism

B. Kerr, J. King, J. Hersh, 2001 .

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 1 Historical and established therapies

S. Broadley, J. Lechner-Scott, M. Slee, 2014, Journal of Clinical Neuroscience.

Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results

B Stubinski, G Giovannoni, G. Giovannoni, 2009, Multiple sclerosis.

Optic nerve decompression in benign intracranial hypertension.

J. King, C. Kilpatrick, J. Galbraith, 1981, Clinical and experimental neurology.

MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis

S. Broadley, J. Lechner-Scott, M. Slee, 2021, Frontiers in Neurology.

Incidence and prevalence of NMOSD in Australia and New Zealand

K. Dear, S. Broadley, J. Lechner-Scott, 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

Fragile X-associated tremor/ataxia syndrome: An under-recognised cause of tremor and ataxia

F. Gaillard, J. King, Sarah Kalus, 2016, Journal of Clinical Neuroscience.

Central nervous system lymphoma associated with natalizumab

J. King, B. Kavar, N. Hall, 2014, Journal of Clinical Neuroscience.

Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome

L. Leocani, M. Filippi, M. Rocca, 2013, Multiple sclerosis.

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy

S. Broadley, J. Lechner-Scott, M. Slee, 2014, Journal of Clinical Neuroscience.

IIIb study in patients with relapsing multiple sclerosis : 96-week results-1 a ( Rebif ® New Formulation ) in a Phase β Safety and immunogenicity of a new formulation of interferon

G. Giovannoni, B. Stubinski, G. Pardo, 2009 .

Copper in urine and hair in Indian childhood cirrhosis

M. F. Smith, J. King, A. M. Ward, 2006 .

The multiple sclerosis PRISMS study: Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis

D. Bates, L. Kappos, H. Hartung, 1997 .

039 Rates of lymphopenia in years 1–4 in patients with relapsing multiple sclerosis treated annually with cladribine tablets

P. Vermersch, G. Comi, P. Sørensen, 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

Reduced immunogenicity with a new formulation of interferon-beta-1a (Rebif (R)): 24-week results of a phase IIIb study

P. Sørensen, G. Giovannoni, B. Stubinski, 2006 .

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

F Fazekas, M Filippi, G Comi, 2009, The Lancet.

Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination

S. Broadley, A. Kermode, D. Wakefield, 2019, Acta Neuropathologica Communications.

Interferons in relapsing remitting multiple sclerosis

H. Hartung, J. Oger, M. Freedman, 2003, The Lancet.